eli lilly retatrutide phase 3 trial Medscape | Retatrutide, Lilly's first-in-class triple hormone receptor agonist, delivered meaningful weight loss at 80 weeks in all doses in the ADA 2026: Retatrutide Revolution

Follow-up period ranged from 1 to 93 months

It is a lazy GLP-1 diet plan because some weeks your energy is gone, your appetite is strange, and cooking feels way too ambitious for the day you are actually having

Abstract Glucagon-like peptide 1 (GLP-1)-based therapies, such as semaglutide and tirzepatide, represent highly effective treatment options for people with type 2 diabetes and obesity, enabling effective control of glucose and weight loss, while reducing cardiovascular and renal morbidity and mortality

The gut microbiota, obesity and insulin resistance

The platform integrates nutrition coaching, realistic physical activity goals, and emotional health support to help you manage stress and maintain long-term success